{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T14:51:53Z","timestamp":1770994313870,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"UK National Screening Committee"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13023-017-0696-z","type":"journal-article","created":{"date-parts":[[2017,9,11]],"date-time":"2017-09-11T11:51:11Z","timestamp":1505130671000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Evaluation of pre-symptomatic nitisinone treatment on long-term outcomes in Tyrosinemia type 1 patients: a systematic review"],"prefix":"10.1186","volume":"12","author":[{"given":"Julia","family":"Geppert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Stinton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karoline","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah","family":"Fraser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aileen","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Sutcliffe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sian","family":"Taylor-Phillips","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,9,11]]},"reference":[{"issue":"3","key":"696_CR1","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s100240010146","volume":"4","author":"PA Russo","year":"2001","unstructured":"Russo PA, Mitchell GA, Tanguay RM. Tyrosinemia: a review. Pediatr Dev Pathol. 2001;4(3):212\u201321.","journal-title":"Pediatr Dev Pathol"},{"key":"696_CR2","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1750-1172-8-8","volume":"8","author":"C Laet de","year":"2013","unstructured":"de Laet C, Dionisi-Vici C, Leonard JV, et al. Recommendations for the management of tyrosinaemia type 1. Orphanet J Rare Dis. 2013;8:8.","journal-title":"Orphanet J Rare Dis"},{"key":"696_CR3","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/8904_2014_363","volume":"19","author":"F Angileri","year":"2015","unstructured":"Angileri F, Bergeron A, Morrow G, et al. Geographical and ethnic distribution of mutations of the Fumarylacetoacetate Hydrolase gene in hereditary Tyrosinemia type 1. JIMD Rep. 2015;19:43\u201358.","journal-title":"JIMD Rep"},{"issue":"10","key":"696_CR4","doi-asserted-by":"crossref","first-page":"4641","DOI":"10.1073\/pnas.74.10.4641","volume":"74","author":"B Lindblad","year":"1977","unstructured":"Lindblad B, Lindstedt S, Steen G. On the enzymic defects in hereditary tyrosinemia. Proc Natl Acad Sci U S A. 1977;74(10):4641\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"696_CR5","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1006\/mgme.1998.2695","volume":"64","author":"J Poudrier","year":"1998","unstructured":"Poudrier J, Lettre F, Scriver CR, et al. Different clinical forms of hereditary tyrosinemia (type I) in patients with identical genotypes. Mol Genet Metab. 1998;64(2):119\u201325.","journal-title":"Mol Genet Metab"},{"issue":"10","key":"696_CR6","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1111\/j.1469-8749.2011.04048.x","volume":"53","author":"C Laet De","year":"2011","unstructured":"De Laet C, Terrones Munoz V, Jaeken J, et al. Neuropsychological outcome of NTBC-treated patients with tyrosinaemia type 1. Dev Med Child Neurol. 2011;53(10):962\u20134.","journal-title":"Dev Med Child Neurol"},{"issue":"5","key":"696_CR7","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1002\/hep.1840200513","volume":"20","author":"FJ Spronsen van","year":"1994","unstructured":"van Spronsen FJ, Thomasse Y, Smit GP, et al. Hereditary tyrosinemia type I: a new clinical classification with difference in prognosis on dietary treatment. Hepatology. 1994;20(5):1187\u201391.","journal-title":"Hepatology"},{"issue":"4","key":"696_CR8","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/j.1399-3046.2011.01497.x","volume":"15","author":"R Arnon","year":"2011","unstructured":"Arnon R, Annunziato R, Miloh T, et al. Liver transplantation for hereditary tyrosinemia type I: analysis of the UNOS database. Pediatr Transplant. 2011;15(4):400\u20135.","journal-title":"Pediatr Transplant"},{"issue":"8823","key":"696_CR9","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/0140-6736(92)92685-9","volume":"340","author":"S Lindstedt","year":"1992","unstructured":"Lindstedt S, Holme E, Lock EA, et al. Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase. Lancet (London, England). 1992;340(8823):813\u20137.","journal-title":"Lancet (London, England)"},{"issue":"1\u20132","key":"696_CR10","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ymgme.2012.05.022","volume":"107","author":"J Larochelle","year":"2012","unstructured":"Larochelle J, Alvarez F, Bussieres JF, et al. Effect of nitisinone (NTBC) treatment on the clinical course of hepatorenal tyrosinemia in Quebec. Mol Genet Metab. 2012;107(1\u20132):49\u201354.","journal-title":"Mol Genet Metab"},{"issue":"3","key":"696_CR11","doi-asserted-by":"crossref","first-page":"210","DOI":"10.4212\/cjhp.v68i3.1454","volume":"68","author":"M Simoncelli","year":"2015","unstructured":"Simoncelli M, Samson J, Bussieres JF, et al. Cost-consequence analysis of Nitisinone for treatment of Tyrosinemia type I. Can J Hosp Pharm. 2015;68(3):210\u20137.","journal-title":"Can J Hosp Pharm"},{"issue":"3","key":"696_CR12","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s10545-008-0817-x","volume":"31","author":"S Santra","year":"2008","unstructured":"Santra S, Preece MA, Hulton SA, et al. Renal tubular function in children with tyrosinaemia type I treated with nitisinone. J Inherit Metab Dis. 2008;31(3):399\u2013402.","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"696_CR13","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s10545-008-0793-1","volume":"31","author":"A Masurel-Paulet","year":"2008","unstructured":"Masurel-Paulet A, Poggi-Bach J, Rolland MO, et al. NTBC treatment in tyrosinaemia type I: long-term outcome in French patients. J Inherit Metab Dis. 2008;31(1):81\u20137.","journal-title":"J Inherit Metab Dis"},{"issue":"8","key":"696_CR14","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1136\/archdischild-2014-306886","volume":"100","author":"PJ McKiernan","year":"2015","unstructured":"McKiernan PJ, Preece MA, Chakrapani A. Outcome of children with hereditary tyrosinaemia following newborn screening. Arch Dis Child. 2015;100(8):738\u201341.","journal-title":"Arch Dis Child"},{"issue":"1","key":"696_CR15","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13023-017-0599-z","volume":"12","author":"C Stinton","year":"2017","unstructured":"Stinton C, Geppert J, Freeman K, et al. Newborn screening for Tyrosinemia type 1 using succinylacetone - a systematic review of test accuracy. Orphanet J Rare Dis. 2017;12(1):48.","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"696_CR16","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1524-475X.2004.04006.x","volume":"1","author":"BH Thomas","year":"2004","unstructured":"Thomas BH, Ciliska D, Dobbins M, et al. A process for systematically reviewing the literature: providing the research evidence for public health nursing interventions. Worldviews Evid Based Nurs. 2004;1(3):176\u201384.","journal-title":"Worldviews Evid Based Nurs"},{"issue":"5","key":"696_CR17","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s10545-014-9683-x","volume":"37","author":"DC Bartlett","year":"2014","unstructured":"Bartlett DC, Lloyd C, McKiernan PJ, et al. Early nitisinone treatment reduces the need for liver transplantation in children with tyrosinaemia type 1 and improves post-transplant renal function. J Inherit Metab Dis. 2014;37(5):745\u201352.","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"696_CR18","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s13023-014-0107-7","volume":"9","author":"S Mayorandan","year":"2014","unstructured":"Mayorandan S, Meyer U, Gokcay G, et al. Cross-sectional study of 168 patients with hepatorenal tyrosinaemia and implications for clinical practice. Orphanet J Rare Dis. 2014;9(1):107.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"696_CR19","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s13023-016-0472-5","volume":"11","author":"WG Ginkel van","year":"2016","unstructured":"van Ginkel WG, Jahja R, Huijbregts SC, et al. Neurocognitive outcome in tyrosinemia type 1 patients compared to healthy controls. Orphanet J Rare Dis. 2016;11(1):87.","journal-title":"Orphanet J Rare Dis"},{"key":"696_CR20","doi-asserted-by":"crossref","first-page":"g6802","DOI":"10.1136\/bmj.g6802","volume":"349","author":"JJ Gagne","year":"2014","unstructured":"Gagne JJ, Thompson L, O'Keefe K, et al. Innovative research methods for studying treatments for rare diseases: methodological review. BMJ. 2014;349:g6802.","journal-title":"BMJ"},{"issue":"3","key":"696_CR21","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ejca.2014.10.027","volume":"51","author":"J Bogaerts","year":"2015","unstructured":"Bogaerts J, Sydes MR, Keat N, et al. Clinical trial designs for rare diseases: studies developed and discussed by the international rare cancers initiative. Eur J Cancer. 2015;51(3):271\u201381.","journal-title":"Eur J Cancer"},{"key":"696_CR22","unstructured":"Bazian L. Screening for Tyrosinaemia I. External review against programme appraisal criteria for the UK National Screening Committee (UK NSC). legacy.screening.nhs.uk\/policydb_download.php?doc=474: NSC UK National Screening Committee, 2014."}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-017-0696-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T17:35:48Z","timestamp":1750872948000},"score":1,"resource":{"primary":{"URL":"http:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-017-0696-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,11]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["696"],"URL":"https:\/\/doi.org\/10.1186\/s13023-017-0696-z","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,11]]},"article-number":"154"}}